Natural history study of allergic inflammation and immune disorders
Official title: Natural History Study for Genetic Diseases of Allergic Inflammation and Immune Dysregulation
Run by Columbia University · NCT05584488 · Data updated 2026-11-12
This study is looking at people with genetic allergies and immune issues to see how their bodies work and improve how we diagnose and treat these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 99 Years |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Columbia University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | July 16, 2010 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | February 4, 2026 |
| Trial ID | NCT05584488 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals of any age with suspected or confirmed inherited disorders of allergic inflammation or immune dysregulation.
✕Probably not a fit
Patients with acquired immune system abnormalities, such as those undergoing chemotherapy or with malignancies, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates individuals with suspected or identified genetic diseases related to allergic inflammation and immune dysregulation. Participants, including their family members, will provide various biological samples such as blood, saliva, and tissue biopsies for research aimed at understanding the genetic and immunological underpinnings of these conditions. The study seeks to correlate clinical evaluations with laboratory findings to enhance the diagnosis and management of atopic diseases and immune disorders. By investigating both known and novel disorders, the research aims to uncover critical insights into the mechanisms of allergic inflammation.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and management strategies for patients with allergic and immune disorders.
How similar studies have gone: Other studies focusing on genetic and immunological aspects of allergic diseases have shown promise, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation, or mast cell homeostasis, or activation or immune dysregulation. * Blood relatives of enrolled subjects will be eligible for enrollment. * There will be no discrimination as to age, gender, race, or disability. * Subjects/guardians must be willing and able to give informed consent. * Subjects must agree to have their blood stored for future studies of the immune system and/or other medical conditions. Exclusion Criteria: • The presence of an acquired abnormality of the immune system, such as cytotoxic chemotherapy or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation.
Where it's running
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Joshua D. Milner, MD — Columbia University
- Study coordinator: Joshua D. Milner, MD
- Email: jdm2249@cumc.columbia
- Phone: 212-305-2100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Global Shwachman-Diamond Syndrome Patient Survey and Collaboration Platform
An online program for people with Shwachman-Diamond Syndrome and their families to share health experiences, join a global community, and receive early information about research and clinical opportunities.
-
R-MVST cell therapy for viral infections in children and young adults
This will try giving rapidly generated virus-specific T cells (R-MVST) to children and young adults whose weakened immune systems have recurrent or treatment-resistant infections with EBV, CMV, adenovirus, or BK virus.
-
A tool to improve family communication in pediatric stem cell transplant decisions
This study is testing a new tool to help families talk better and make decisions together about stem cell transplants for kids aged 8 to 17.
-
Understanding X-linked Moesin Associated Immunodeficiency
This study looks at how to better treat boys with X-linked Moesin Associated Immunodeficiency by collecting health information to understand their infections and the effects of their genetic mutations.
-
Improving immune function in older adults with a new immunomodulator
This study is testing a new treatment called QBKPN to see if it can boost the immune system in older adults aged 65 and up and help them stay healthier, especially against respiratory infections.
-
Understanding immune response in sepsis and septic shock
This study looks at how the immune system reacts in people with sepsis and septic shock to see if understanding these responses can help improve treatment in the future.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.